首页> 外文期刊>Vaccine >Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV
【24h】

Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV

机译:重组禽痘病毒,质粒和病毒样颗粒在针对SHIV的初次加强免疫接种方案中的联合使用对兔产生的免疫应答和细胞因子谱的比较分析

获取原文
获取原文并翻译 | 示例
           

摘要

Three different prime-boost immunization protocols were tested in rabbits and their immune response was evaluated and compared with the final aim of identifying a-vaccine strategy that might be able to protect non-human primates from infection with the pathogenic chimera simian/human immunodeficiency virus (SHIV)(89.6P). Protocols were based on priming with two fowlpox (FP) recombinant vectors and two expression plasmids, which express either the simian immunodeficiency virus (SIV)mac(239) gag/pol or the human immunodeficiency virus (HlV-1)env(89.6P) genes, followed by boosting with virus-like particles (VLP). All protocols were effective in eliciting homologous neutralizing Ab and highlighted the efficacy of VLP boosting. The FP vector was less efficient than plasmid DNA in inducing Ab against the gag core proteins. Analysis of cytokine expression 5 months after last immunization indicated that priming with pcDNA3gag/pol(SIV) and FPenv(89.6P) followed by VLP boosting generated a T helper (Th0) profile and a good Ab titer, suggesting a potential protocol to be tested in the SHIV-macaque model of HIV-1 infection.
机译:在兔子中测试了三种不同的初免-加强免疫方案,并对它们的免疫反应进行了评估,并将其与最终确定a-疫苗策略的最终目的进行了比较,该策略可能能够保护非人类灵长类动物免受致病性嵌合猿/人类免疫缺陷病毒的感染(SHIV)(89.6P)。协议基于两个鸡痘(FP)重组载体和两个表达质粒的启动,它们表达猿猴免疫缺陷病毒(SIV)mac(239)gag / pol或人免疫缺陷病毒(HlV-1)env(89.6P)基因,然后用病毒样颗粒(VLP)增强。所有方案均有效引起同源中和抗体,并强调了VLP加强的功效。 FP载体在诱导针对gag核心蛋白的Ab方面不如质粒DNA有效。上次免疫后5个月对细胞因子表达的分析表明,先用pcDNA3gag / pol(SIV)和FPenv(89.6P)进行初次接种,然后进行VLP增强,可产生T辅助(Th0)谱和良好的Ab滴度,表明有待测试的潜在方案在HIV-1感染的SHIV-猕猴模型中。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号